• About Nektar
  • Our Leadership
  • Corporate Giving
  • Locations
  • Contacts
• Pipeline
  • Pipeline Overview
  • Nektar Proprietary Products
  • Nektar Partnered Products
  • Drug Development Platforms
• Partners
  • Nektar Partners
• Investor Relations
  • Press Releases
  • Stock Information
  • Financial Events Calendar
  • Analyst Coverage
  • Annual and Financial Reports
  • Corporate Governance
  • Investor Contacts
  • FAQ
  • Investor Advisory
• Media Room
  • Lead Product Backgrounder
  • Press Releases
  • Press Kit
  • Media Contacts
• Information Center
  • Scientific & Partnering Events
  • Multimedia
  • Library
  • Email Alerts
• Careers
  • Life at Nektar
  • Career Opportunities
  • Recruitment Calendar
  • Summer Internships
  • Benefits
  • Recruiting Information
  • Nektar Employee Foundation

• Pipeline Overview
• Nektar Proprietary Products
• Nektar Partnered Products
• Drug Development Platforms
  • Advanced PEGylation Technology
  • Advanced Pulmonary Delivery
    • Dry Powder Pulmonary Technology
    • Liquid Pulmonary Technology

Our scientists pioneered the development of fine, aerodynamic drug particles for efficient dispersibility and reproducible delivery to the lung. And today, with more than a decade of experience in solving difficult formulation challenges, we are the industry leader in advanced pulmonary delivery.

As a noninvasive alternative to injection, the pulmonary delivery route offers opportunities for improved and innovative drug delivery and greater patient compliance. In addition, pulmonary delivery offers rapid onset of action and more efficient and targeted treatment of lung disorders.

Nektar Advanced Pulmonary Delivery combines innovations in dry powder and liquid pulmonary technology with state-of-the-art devices that deliver both large and small molecules to the lung for both systemic and local drug administration.